1. Home
  2. IDN vs XBIT Comparison

IDN vs XBIT Comparison

Compare IDN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$2.41

Market Cap

56.5M

Sector

Technology

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.17

Market Cap

66.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDN
XBIT
Founded
1994
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.5M
66.8M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
IDN
XBIT
Price
$2.41
$2.17
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $7.33
N/A
AVG Volume (30 Days)
★ 297.2K
43.6K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 220.00
N/A
EPS
★ 0.06
N/A
Revenue
★ $4,433,454.00
N/A
Revenue This Year
$12.54
N/A
Revenue Next Year
$15.32
N/A
P/E Ratio
$40.00
★ N/A
Revenue Growth
★ 23.21
N/A
52 Week Low
$2.32
$2.09
52 Week High
$9.08
$3.44

Technical Indicators

Market Signals
Indicator
IDN
XBIT
Relative Strength Index (RSI) 31.57 40.04
Support Level N/A N/A
Resistance Level $3.00 $2.48
Average True Range (ATR) 0.09 0.04
MACD 0.02 0.00
Stochastic Oscillator 18.02 15.38

Price Performance

Historical Comparison
IDN
XBIT

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: